Novo Nordisk keeps nose ahead of Lilly with oral GLP-1 filing
Shares in Eli Lilly (NYSE: LLY) shot up last Thursday after the US pharma major announced positive top-line Phase III results from ACHIEVE-1, comparing orforglipron to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone.
The impressive data confirmed orforglipron as a frontrunner in the race to introduce the first oral glucagon-like peptide-1 (GLP-1) receptor agonist to the market, with its potential as a convenient once-daily pill for obesity making it a lucrative prospect, in particular.
But Lilly has a rival in the race, that being Novo Nordisk (NOV: N), and the Danish drugmaker is in fact currently in pole position, having already submitted an application to the US Food and Drug Administration (FDA) seeking approval of an oral version of its GLP-1 receptor agonist Wegovy (semaglutide).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze